Watson Health And Pfizer Partner To Harness Big Data For Drug Discovery

The advanced data analytics provider IBM Watson Health has signed its first big pharma partner – Pfizer – for a new drug discovery tool, with a focus on immuno-oncology.

The advanced data analytics provider IBM Watson Health has signed its first big pharma partner, Pfizer Inc., for a new computational tool called Watson for Drug Discovery. Pfizer will use Watson’s new cloud-based data analytics tool to discover new drugs faster in the area of immuno-oncology, with a focus on discovery of new and unexplored drug targets, potential combination therapies and patient selection strategies.

The companies announced the collaboration Dec. 1 at the Forbes Healthcare Summit in New York City.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immuno-oncology

More from Anticancer

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By 

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.